HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Lenvatinib
Related studies linked through entity extraction aliases.
Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
- Status
- WITHDRAWN
- Phase
- PHASE1
The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- NA
AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC
- Status
- WITHDRAWN
- Phase
- PHASE2
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
- Status
- RECRUITING
- Phase
- NA
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
- Status
- COMPLETED
- Phase
- PHASE2
Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
- Status
- RECRUITING
- Phase
- PHASE2
Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3